Introduction
In addition to antiepileptic drugs (AEDs), people with epilepsy also take concomitant medicines (CMs) for a number of reasons. This is mainly due to concomitant diseases which are frequent in this group. Population studies indicate that people with epilepsy have a two-to five-fold increase in occurrence of most chronic psychiatric and somatic conditions compared with the general population. [1] [2] [3] These include such conditions as migraine, cerebrovascular and cardiovascular disorders, gastrointestinal disorders, depression, anxiety, and personality disorders. CMs used for these conditions often have clinically significant drug-drug interactions which occur with agents that interact with the cytochrome P450 pathway, including AEDs. 4 The high prevalence of comorbidities and the ensuing need to use CMs requires increased access to healthcare and substantially increases its costs. 5 The second reason for CM use by people with epilepsy is easy access to over-the-counter (OTC) complementary medicines. According to various studies, this applies to more than 30% of patients. [6] [7] [8] About one-fourth use them specifically for their epilepsy 9 and the majority use them for general health conditions. 6 Vitamins and herbal medicines are one of the most common forms of complementary medicines. However, some of the most popular herbal remedies are known to act on the cytochrome P450 system, with potential effects on AED levels, and some of them exhibit proconvulsive effects. 10 Because fewer than 40% of patients report use of these substances to their physicians, the consequences are often hazardous. 10 Comedication is especially problematic in older patients and it has received appropriate attention. Less information is available, however, about medication habits and their costs in younger patients with chronic epilepsy. This paper is complementary to a prospective multicentre project estimating global annual costs of epilepsy in Poland in 2006. 11, 12 
Materials and methods
The prospective study was conducted in 18 Patients who have had 3, 6 or 9-month observation were not included in this analysis. Demographic and treatment characteristics of the patients are presented in Table 1 . Data on clinical characteristics and CMs were collected in a standardized way, based on five questionnaires. The first questionnaire was used to collect baseline data during the first visit and the next four were completed quarterly by the neurologists during patients' consecutive visits. Fig. 1 presents the number of AEDs administered in 767 patients (in five patients no AEDs were administered due to seizure remission). 13 AEDs were divided into enzyme-inducing AEDs including carbamazepine (CBZ), phenytoin (PHT), primidon (PRM) and phenobarbital (PB), and non-inducing AEDs (all other AEDs used).
CMs were defined as any no-AED medicines used sporadically or chronically by patients during the 1-yr observation period. The use of more than 120 tablets of any medicines per year was considered as chronic treatment. Acute or sporadic use referred to use of less than 120 tablets. All medicines were classified according to the Anatomical Therapeutic Chemical (ATC) Classification System.
14 In this paper we took into consideration 1st level (main groups) and 2nd level (pharmacological/therapeutic subgroups) codes for all medicines, and 3rd and 5th level codes for the most frequently used medicines (chemical/pharmacological/therapeutic subgroups and chemical substance), respectively. The number of patients receiving medicines from the main groups (level 1) corresponds to the number of patients who took any drug from the main groups. The number of patients using drugs from subgroups (level 2) may be higher than the number given in main groups (level 1) because some patients took more than one drug from different subgroups. 
Results

Patients on CMs
Of the 772 patients with epilepsy, 472 (61.1%) used 1607 drugs other than AEDs during 1 yr of observation (3.4 drug/patient). Of 1607 medicines 922 (57.4%) were used as an acute or sporadic 
Use of CMs
Fourteen groups of drugs used by the patients, classified according to the ATC system, are listed in Table 2 . The most frequently used CMs belonged to the alimentary tract and metabolism group (A) -465 (28.9%) CM, nervous system group (N) -318 (19.8%) CM and cardiovascular system group (C) -178 (11%) CM. Drugs from other groups accounted for less than 10% each.
Main group A medicines
CMs from group A were taken by 269 patients (57.0%). Table 3 presents the most common drugs from group A: vitamins (50.1%), mineral supplements (17.4%), drugs for acidic disorders (8.4%), functional gastrointestinal disorders (7.0%), and bile and liver therapy (6.5%). Together these drugs accounted for 90% of all drugs from group A.
There were no significant age and gender differences in number of patients between patients taking drugs from group A and those not taking drugs.
Main group N medicines
The second most frequently used group N consisted of psychoanaleptics (36.8%), analgesics (31.1%) and psycholeptics (29.8%), taken by 95, 81 and 73 patients, respectively. Other drugs constituted 2.2% (Table 3) .
Among the psychoanaleptics, nootropic drugs and agents used for ADHD constituted 56.4% and antidepressants -43.6%. The latter group included new class drugs -selective serotonin reuptake inhibitors, selective serotonin reuptake enhancers, serotoninnonepinephrine reuptake inhibitors (67.3%) and older class drugstricyclic antidepressants and monoamino oxidase inhibitors (37.7%).
Psycholeptics comprised antipsychotics (51.6%) and anxiolytics and sedatives (48.4%). Antipsychotics included typical (67.3%) and atypical (32.7%) drugs.
There were no gender or age differences in CM use between patients taking and not taking drugs from group N.
Main group C medicines
Among drugs from group C, taken by 84 patients (17.8%), the following were used most frequently: agents acting on the reninangiotensin system (25.8%), beta blocking agents (17.9%), lipid modifying agents (15.7%), diuretics (14.6%) and calcium channel blockers (9.5%). These drugs constituted more than 80% of all drugs from group C (Table 3) .
In patients treated with cardiovascular drugs, the mean age (45.6 yrs) was significantly greater than in the remaining group (28.1 yrs), p > 0.0001. Use of those medications increased with age (Fig. 2 ).
There were no gender differences in use of CM between patients taking and not taking medicines from group C. Thirty-five (7.4%) women were taking sex hormones, mostly oral contraceptives (OCs). All of those OCs contained <50 mg of estrogen.
The most commonly used drugs in level 2 groups were: vitamins (14.7%), antibacterials (7.3%), psychoanaleptics (7.2%), analgesics (6.1%), antiemetics (6.0%), psycholeptics (5.9%), and mineral supplements (5.0%). The other 59 groups of drugs accounted for less than 5% of use each.
Of the all drugs, the most frequent single medicines (5th level of ATC classification) were vitamin B 6 (117; 7.3%) and folic acid (69; 4.3%). All other single drugs did not exceed 1.5% of use each.
Cost of drugs
Total annual cost of CMs for 472 patients with epilepsy was 76011.9 s PPP (Tables 2 and 3 Linear regression analysis revealed a positive correlation between costs and patients' age, correlation coefficient (r = 0.2); there was no correlation between costs and duration of epilepsy.
Mean annual cost of CMs was higher in persons with chronic concomitant diseases -237.6 s PPP than in persons without such diseases -78. 4 s PPP (p < 0.0001). 
OTC drugs
Two hundred and ninety patients used 580 OTC drugs, mean 2.0 per patient. They constituted 61.4% of those who used any CM. The most common groups of OTC were vitamins (40%), analgesics (15.2%), mineral supplements (11.4%), liver protectors (4.6%), and cold medicines (4.6%). They accounted for 75.8% of all OTC drug usage.
The overall cost of OTC was 13924.5 s PPP (18.3% of cost of all CM), mean cost per patient -48.0 s PPP. Of all OTC, the cost of CM from group A constituted 78.5%. In this group, vitamins, liver protectors and mineral supplements constituted 92.8%.
Patients pay the full price of OTC drugs in Poland. Prescription drugs are either partially reimbursed or fully paid by patients.
Patients covered 53208.3 s PPP (70%) of all CM costs.
Discussion
Use of CMs
Our data confirm the widespread use of CMs in patients with chronic epilepsy. These patients take both drugs used on a shortterm basis and maintenance therapy. The mean number of CMs was 3.4 per patient and 2.08 for the 772-patient group. The material comprises mostly young and middle-aged adults with a fairly small representation of old people (mean age -27.4 yrs; median -25.0) and therefore a smaller number of CMs could be expected than in older patients with epilepsy. However, if AEDs were added, the mean number for the whole group would be 4.07, which is not drastically less then the mean number of CMs and AEDs used by patients with epilepsy in nursing homes -5.6. 15 Therefore, the problem of potential interactions seems to be common and not limited only to the oldest population. More than 40% of patients taking CMs also received enzyme-inducing AEDs which may reciprocally interfere with drug metabolism.
Almost 2/3 of all the CMs in our group were OTC drugs. Many of them, like vitamins, mineral supplements, and herbal preparations, are self-administered without the physician's knowledge 6 and are potentially proconvulsive or harmful. It is worth noting that the most common reason why doctors are not aware of this is that they do not ask. 8 Generally, CMs were taken significantly more frequently by woman than men (58.7 vs. 41.3%); a similar pattern was found in the general population in Poland, i.e. 61% vs. 46%. 16 However, no significant gender differences in use were found when three major groups of CMs, alimentary, nervous and cardiovascular system, were analyzed separately. As it could be expected, the patients taking CMs were significantly older, had longer duration of epilepsy, more frequent concomitant diseases, and more seizures than patients not receiving any CM.
The most common medicines were vitamins, followed by psychotropic and cardiac medications. Those two latter groups were also found to be most frequently administered in older patients with epilepsy in nursing homes. 15 
Vitamins
Vitamins were the most commonly used CM in the study group (14.7% of use), taken by 40.2%, and together with mineral supplements, by 55%. Vitamins and mineral supplements were also the most frequently taken medicines in the general population in Poland -20% of adults and 49.4% of children <15 yrs. 16 Of all the CMs, the single most frequently used drugs were vitamin B 6 (7.3%) and folic acid. In the past it was customary to administer vitamin B 6 with then used AEDs, such as phenytoin and its derivatives, to protect from leukopenia. This still may be the habit among neurologists and patients in Poland although phenytoin use is now extremely rare. The more general question now is the rationale for the use of such quantities of vitamin and mineral supplements, especially in this rather young group of patients, a habit which is contributing relevantly to their personal expenses.
Psychotropic drugs
Psychiatric disorders occur more frequently in patients with epilepsy than in the general population. 2 Physicians are often reluctant to use psychotropic medications in epileptic patients with psychiatric disorders because of the potential risk of lowering the seizure threshold. Several pharmacokinetic and pharmacodynamic interactions, often with important clinical consequences, between antidepressants, antipsychotics and AEDs are known. AED inducers increase the clearance of all the antipsychotics, which may require dosage adjustment. 17 In our material, psychoanaleptics and psycholeptics constituted 13.1% of all CMs used by 35.6% of patients and as a group of drugs used for nervous system disorders were the second according to frequency of use. In older patients with epilepsy, these are the drugs most frequently used as comedication. 15, 18 Antidepressant, neuroleptic and anxiolytic drugs are by far the most frequently prescribed drugs in patients with mental retardation. Among our patients who were using CMs, intellectual impairment (in various degrees, mostly mild) occurred in quite a large percentage, i.e. in 15.0% of patients. 19 These patients are characterized by an increased incidence of comorbidity, often with psychiatric disorders which may require treatment with other medicines. As a group, these patients may be particularly vulnerable to problems associated with polytherapy. 20 From a practical point of view, it is important to consider the potential effect of CMs (mostly sedatives) on cognitive functioning, often falsely suggesting negative AED effects.
Cardiovascular drugs
Cardiovascular drugs were the third most commonly used drugs and among those used most frequently were hypertensives. The use of these medicines increased with age, as cardiovascular diseases are more frequent in the older population. Hypertension is the most frequent disease in the general population in Poland 16 and also the most frequent somatic disorder in persons with epilepsy in our material. Generally, enzyme-inducing AEDs enhance the metabolic clearance of several cardiovascular agents with a consequent reduction in their plasma levels and therapeutic efficacy. The most relevant interactions are interactions with calcium channel blockers and warfarin. In fact, in the case of nimodipine, the decline of plasma concentration may be up to sevenfold. 21 Conversely, interactions involving inhibition of AEDs by concomitantly administered cardiovascular drugs may also be important and may cause toxic effects. 22 
Other CMs
Many other less frequently used CMs may exhibit clinically important interactions with AEDs. For example, AEDs and hormones have a bidirectional interaction that can impair the efficacy of contraceptive hormone treatments and the efficacy of AEDs. 23 OCs are prescribed for 16.7% of fertile age women with epilepsy. 24 In our group, the percentage of sex hormone use (mostly OCs) was smaller (7.4%), it was also smaller in comparison with the general population in Poland. 25 However, use of OCs in Poland remains one of the smallest in Europe. 26 All the OCs used contained <50 mg of estrogen with the potential of important interaction with some AEDs. Antimicrobials are the other example of possible interference with AED metabolism. 22 Nearly 20% of patients in the material used antibiotics including macrolides, which strongly inhibits CBZ metabolism and is potentially toxic.
Cost of CMs
The mean annual cost of CM per patient was 161.0 s PPP with a wide spread from 1.1 to 2400.7 s PPP. It was substantially lower then the mean annual cost of AEDs per patient -1019.8 s PPP. 11 However, due to the reimbursement system, in case of AEDs, patients paid out of their pocket nearly 8% of all expenses, and in case of CM, patients covered 70% of all CM costs. This is a relevant personal expense for the patients who are often unemployed and use social care benefits.
Summary and conclusions
Patients with epilepsy, regardless of age, take commonly CMs. Nearly 2/3 of patients with epilepsy took at least one CM (3.4 drug/patient) during the 1-yr observation period. More women than men took CMs. The patients taking CMs were significantly older, had longer duration of epilepsy, more frequent concomitant diseases, and more seizures than patients not receiving any CM. The most frequently used drugs were vitamins and mineral supplements, followed by psychotropic and cardiovascular drugs. OTC drugs constituted nearly 2/3 of all CMs. The mean annual cost of CMs per patients was much smaller in comparison with the cost of AEDs but was still a relevant personal expense. Consideration for the potential interactions and consequences of the common use of CMs, especially OTC drugs, in patients with epilepsy should urge physicians to pay more attention to this issue.
